Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with moderate disease. A strategy associated with a reduction in hospital admissions and complications

José A. Oteo, Pedro Marco, Luis Ponce de León, Alejandra Roncero, Teófilo Lobera, Valentín Lisa
doi: https://doi.org/10.1101/2020.06.10.20101105
José A. Oteo
1Infectious Disease Department. Hospital Universitario San Pedro and Center of Biomedical Research of La Rioja (CIBIR). Piqueras 98. 26006 Logroño (Spain)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jaoteo@riojasalud.es
Pedro Marco
2Emergency Department. Hospital Universitario San Pedro. Piqueras 98. 26006 Logroño (Spain)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Ponce de León
3Hospital Home-Care Unit. Piqueras 98. 26006 Logroño (Spain)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alejandra Roncero
3Hospital Home-Care Unit. Piqueras 98. 26006 Logroño (Spain)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teófilo Lobera
3Hospital Home-Care Unit. Piqueras 98. 26006 Logroño (Spain)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valentín Lisa
2Emergency Department. Hospital Universitario San Pedro. Piqueras 98. 26006 Logroño (Spain)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

SUMMARY

The new SARS-CoV-2 infection named COVID-19 has severely hit our Health System. At the time of writing this paper no medical therapy is officially recommended or has shown results in improving the outcomes in COVID-19 patients. With the aim of diminishing the impact in Hospital admissions and reducing the number of medical complications, we implemented a strategy based on a Hospital Home-Care Unit (HHCU) using an easy-to-use treatment based on an oral administration regimen outside the hospital with hydroxychloroquine (HCQ) plus azithromycin (AZM) for a short period of 5 days.

Patients and methods Patients ≥ 18 years old visiting the emergency room at the Hospital Universitario San Pedro de Logroño (La Rioja) between March, 31st and April, 12th diagnosed with COVID-19 with confirmed SARS-CoV-2 infection by a specific PCR, as follows: Patients with pneumonia (CURB ≤ 1) who did not present severe comorbidities and had no processes that contraindicated this therapeutic regime. Olygosimptomatic patients without pneumonia aged ≥ 55 years. Patients ≥ 18 years old without pneumonia with significant comorbidities. We excluded patients with known allergies to some of the antimicrobials used and patients treated with other drugs that increase the QTc or with QTc >450msc. The therapeutic regime was: HCQ 400 mg every twice in a loading dose followed by 200 mg twice for 5 days, plus AZM 500 mg on the first day followed by 250 mg daily for 5 days. A daily telephone follow-up was carried out from the hospital by the same physician.

The end-points of our study were: 1.- To measure the need for hospital admission within 15 days after the start of treatment. 2.- To measure the need to be admitted to the intensive care unit (ICU) within 15 days after the start of the treatment. 3.- To describe the severity of the clinical complications developed. 4.- To measure the mortality within 30 days after starting treatment (differentiating if the cause is COVID-19 or something else). 5.-To describe the safety and adverse effects of the therapeutic regime.

Results During the 13 days studied a total of 502 patients were attended in the emergency room due to COVID-19. Forty-two were sent at home; 80 were attended by the HHCU (patients on this study) and 380 were admitted to the Hospital. In our series there were a group of 69 (85.18%) patients diagnosed with pneumonia (37 males and 32 females). Most of them, 57 (82.60%) had a CURB65 score of <1 (average age 49) and 12 (17.40%) a CURB score of 1 (average age 63). Eighteen (22.50%) of the pneumonia patients also had some morbidity as a risk factor. 11 patients (13.75%) without pneumonia were admitted to the HHCU because comorbidities or age ≥ 55 years. Six patients with pneumonia had to be hospitalized during the observation period, 3 of them because side effects and 3 because of worsening. One of these patients, with morbid obesity and asthma, had clinical worsening needing mechanical ventilation at ICU and developed acute distress respiratory syndrome. With the exception of the patient admitted to the ICU, the rest of the patients were discharged at home in the following 8 days (3 to 8 days).

Twelve patients (15%), 11 of whom had pneumonia, experienced side effects affecting mainly the digestive. In another patient a QTc interval prolongation (452 msc) was observed. In total 3 of these patients had to be admitted in the Hospital, 2 because of vomiting and 1 because a QTc interval lengthening. None of the patients needed to stop the HCQ or AZM and all the 80 patients finished the therapeutic strategy. From the group without pneumonia only a patient developed diarrhea that did not require hospitalization or stop the medication.

Conclusions Our strategy has been associated with a reduction in the burden of hospital pressure, and it seems to be successful in terms of the number of patients who have developed serious complications and / or death. None of the patients died in the studied period and only 6 have to be admitted in conventional hospitalization area.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

We think that our study was misunderstood. This is not a clinical trial. It is an observational study with an intervention that was approved by the Direction of the Hospital. In Spain this treatment was an authorized option with or without a clinical trial.

Funding Statement

No external funding was received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This is not a clinical trial. It is an observational study with an intervention approved by the Direction of the Hospital. At the moment of the study (beginning of April, during the lockdown in Spain), this study was an authorized option in Spain, with or without a clinical trial.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of interest disclosure: Nothing to disclose.

  • Funding: No external funding was received.

Data Availability

All data referred to in the manuscript are available upon request to authors. This kind of study was an authorized option in Spain, with or without a clinical trial. This is not a clinical trial. It is an observational study with an intervention approved by the Direction of the Hospital. A few weeks ago, our healthcare system was on the verge of collapse, we were running out of hospital beds, and with the strategy of a therapeutic approach easy to carry out in a Hospitality Home-Care Unit, we were able to effectively reduce the hospital burden. We think that these data can be useful to expand knowledge in this therapeutic pattern.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 12, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with moderate disease. A strategy associated with a reduction in hospital admissions and complications
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with moderate disease. A strategy associated with a reduction in hospital admissions and complications
José A. Oteo, Pedro Marco, Luis Ponce de León, Alejandra Roncero, Teófilo Lobera, Valentín Lisa
medRxiv 2020.06.10.20101105; doi: https://doi.org/10.1101/2020.06.10.20101105
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with moderate disease. A strategy associated with a reduction in hospital admissions and complications
José A. Oteo, Pedro Marco, Luis Ponce de León, Alejandra Roncero, Teófilo Lobera, Valentín Lisa
medRxiv 2020.06.10.20101105; doi: https://doi.org/10.1101/2020.06.10.20101105

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (945)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
  • Epidemiology (8976)
  • Forensic Medicine (4)
  • Gastroenterology (418)
  • Genetic and Genomic Medicine (1940)
  • Geriatric Medicine (190)
  • Health Economics (401)
  • Health Informatics (1323)
  • Health Policy (657)
  • Health Systems and Quality Improvement (518)
  • Hematology (212)
  • HIV/AIDS (417)
  • Infectious Diseases (except HIV/AIDS) (10780)
  • Intensive Care and Critical Care Medicine (573)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (221)
  • Neurology (1820)
  • Nursing (109)
  • Nutrition (271)
  • Obstetrics and Gynecology (352)
  • Occupational and Environmental Health (470)
  • Oncology (995)
  • Ophthalmology (297)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1894)
  • Public and Global Health (4117)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (364)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)